相关实验视频
Updated: Jul 13, 2026

07:35
Gene Transfer for Ischemic Heart Failure in a Preclinical Model
Published on: May 15, 2011
用A1选择性腺类类似物进行静脉预治疗可以保护心脏免受心脏病发作的影响
J D Thornton1, G S Liu, R A Olsson
1Department of Physiology, University of South Alabama, Mobile 36688.
Circulation
|February 1, 1992
概括
静脉注射PIA和CCPA等腺素A1受体激动剂可以保护心脏免受心脏病发作. 这种心脏保护是当激动剂在缺血之前给予时才能实现的,而不是在再注射期间.
科学领域:
- 心血管研究研究心血管研究
- 药理学 药理学是指药理学的学科.
- 缺血预先调节 缺血预先调节
背景情况:
- 腺素预治疗通过A1受体保护心脏免受心脏病发作.
- 系统性低血压限制了先前的腺素给药对冠状动脉循环的影响.
研究的目的:
- 调查A1选择性腺激动剂的静脉注射是否可以实现心脏保护.
- 为了确定是否需要在缺血之前激活A1受体以获得保护.
主要方法:
- 开放胸部麻醉的子经历了区域冠状动脉缺血和再输液.
- 使用四粉染法测量了心脏病发作的大小.
- 在缺血之前,A1选择性激动剂 (PIA,CCPA) 和A2选择性激动剂 (CGS 21680) 被静脉注射.
主要成果:
- 静脉注射N6-(-2R-异) -腺素 (PIA) 和2--N6-cyclopentyladenosine (CCPA) 在缺血之前给予时显著减少了心脏病发作的大小.
- 在再注射期间服用PIA并没有提供保护.
- A2受体激动剂CGS 21680未能限制心脏病发作的大小.
- 即使在子被步行时,也观察到保护,排除了心肌梗塞作为机制.
结论:
- 激发腺A1受体会对心脏缺血产生抵抗力.
- 通过静脉注射A1选择性腺剂可以实现对心脏病发作的心脏保护.
相关概念视频
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antianginal Drugs: Nitrates and β-Blockers
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Cardiopulmonary Resuscitation IV: Pharmacological Management
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...

